---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-23-000051"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:49:17.487528+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics reports Q2 loss of $41.2M; initiates Phase 2b IPF trial, expects PSC data Q3 2023

## Summary
- Net loss $41.2M vs $29.5M prior year; R&D $33.0M, G&A $14.6M.
- Cash, equivalents & short-term investments $555.2M; sufficient into H2 2026.
- Initiated Phase 2b BEACON-IPF trial of bexotegrast in IPF (~270 patients, 160/320 mg).
- INTEGRIS-PSC Phase 2a 12-week interim data from 40/80/160 mg cohorts expected Q3 2023.
- Promoted Dr. Scott Turner to Chief Scientific Officer.

## SEC filing metadata
- accession: 0001746473-23-000051
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000051/0001746473-23-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000051/plrx-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-23-000051
- JSON: https://secwatch.observer/filing/0001746473-23-000051.json
- Plain text: https://secwatch.observer/filing/0001746473-23-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.